Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
asset sale
Biotech
Servier supercharges neuro pipeline with $450M deal
Servier plans to launch a phase 2 clinical trial for Fragile X syndrome candidate KER-0193 in Europe and the U.S. next year.
Darren Incorvaia
Sep 8, 2025 2:30am
Portage finds hope in sale of iNKT agonists to Immunova
Dec 17, 2024 8:15am
Amylyx seeks to fill Relyvrio-sized hole with $35M GLP-1 buy
Jun 24, 2024 10:18am
AngioDynamics sheds some catheter products in $45M deal
Feb 16, 2024 10:37am
Basilea anti-infective strategy restarts with $2M antifungal buy
Oct 19, 2023 7:25am
Novo Nordisk buys rival to Bayer's Kerendia in $1.3B deal
Oct 16, 2023 9:30am
